Search Results - "E I Kovalenko"

The Antigen‐Specific Response of NK Cells to SARS‐CoV‐2 Correlates With KIR2DS4 Expression by Ustiuzhanina, M. O., Boyko, A. A., Vavilova, J. D., Siniavin, A. E., Streltsova, M. A., Astrakhantseva, I. V., Drutskaya, M. S., Chudakov, D. M., Kovalenko, E. I.

“…ABSTRACT Natural killer (NK) cells play a pivotal role in the immune response against viral infections, including SARS‐CoV‐2. However, our understanding of…”
Get full text

Increased proliferative response of highly differentiated CD57+NKG2C+NK cells expressing NKG2A by Alekseeva, N. A., Vavilova, Yu. D., Kovalenko, E. I.

“…During infection with cytomegalovirus (HCMV), the content of so-called adaptive NK cells with the CD57 + NKG2C + phenotype increases in the peripheral blood,…”
Get full text

Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review by Avxentyev, N. A., Andreyashkina, I. I., Artamonova, E. V., Bolotina, L. V., Kovalenko, E. I., Sisigina, N. N.

“…At present, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors such as palbociclib, ribociclib, and abemaciclib are widely used for the first-line treatment…”
Get full text

NK cells expansion in vitro is followed by loss of inhibitory KIR expression by Alekseeva, N. A., Ustyuzhanina, M. O., Streltsova, M. A., Grechikhina, M. V., Lutsenko, G. V., Kovalenko, E. I.

“…NK cells are innate lymphocytes that are able to eliminate altered cells, which makes them promising for the immunotherapy of viral diseases and tumors. The NK…”
Get full text

Coordination of NK cell markers expression and IgG response in hCMV infection by Ustiuzhanina, M. O., Vavilova, Ju. D., Alekseeva, N. A., Lutcenko, G. V., Chudakov, D. M., Kovalenko, E. I.

“…Human cytomegalovirus (hCMV) is a prevalent virus that affects a large proportion of the population worldwide. Natural Killer (NK) cells are essential immune…”
Get full text

Efficiency and tolerability of abemaciclib in elderly patients by Kovalenko, E. I., Khoroshilov, M. V., Artamonova, E. V.

“…Elderly cancer patients represent a very heterogeneous population not only in chronological age, but also in functional status, concomitant diseases and…”
Get full text

Hormone therapy for premenopausal women with metastatic breast cancer: combinations with cyclin-dependent kinase inhibitors by Artamonova, E. V., Kovalenko, E. I.

“…This article discusses the problems associated with the search of the most effective treatment strategies for HER2-negative metastatic breast cancer in…”
Get full text

Effect of lipopeptide structure on gene delivery system properties: Evaluation in 2D and 3D in vitro models by Koloskova, O.O., Gileva, A.M., Drozdova, M.G., Grechihina, M.V., Suzina, N.E., Budanova, U.A., Sebyakin, Yu.L., Kudlay, D.A., Shilovskiy, I.P., Sapozhnikov, A.M., Kovalenko, E.I., Markvicheva, E.A., Khaitov, M.R.

“…[Display omitted] •Number of amino acids derivatives in lipopeptide affects the properties of lipoplexes.•Lipoplexes behavior was examined within the cells in…”
Get full text

Adaptive features of natural killer cells, lymphocytes of innate immunity by Kovalenko, E. I., Streltsova, M. A.

“…Natural killer cells (NK cells) are traditionally attributed to the innate immune system. It is considered that previously received stimuli have little effect…”
Get full text

Subpopulation Heterogeneity of NK Cells during the Genetic Modification for Subsequent Use in Targeted Therapy by Streltsova, M. A., Boyko, A. A., Ustiuzhanina, M. O., Palamarchuk, A. I., Alekseeva, N. A., Velichinskii, R. A., Vavilova, J. D., Grechikhina, M. V., Sapozhnikov, A. M., Deev, S. M., Kovalenko, E. I.

“…Obtaining genetically engineered NK cells is a developing area of immunotherapy. In this work, we analyzed the subset heterogeneity of NK cells subjected to…”
Get full text

Umbilical cord blood as a promising source of NK cells for immunotherapy by Velichinskii, R. A., Vavilova, J. D., Boyko, A. A., Shustova, O. A., Palamarchuk, A. I., Yusubalieva, G. M., Kucherova, O. N., Streltsova, M. A., Kovalenko, E. I.

“…Currently, a large number of studies on genetic modification of cord blood NK cells (UCB-NK) are carried out at both clinical and preclinical levels…”
Get full text

CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’ preferences (“Prometheus”) in Russia – first results of the survey by Artamonova, E. V., Kovalenko, E. I., Bolotina, L. V., Stenina, M. B., Orlova, R. V., Mukhina, M. A.

“…The emergence of a new class of drugs – inhibitors of cyclin-dependent kinases 4/6 (CDK4/6) – has changed the paradigm of treatment of patients with luminal…”
Get full text

Microenvironment-related predictive markers of the therapeutic effectiveness of eribulin in patients with locally advanced or metastatic breast cancer: pilot study by Tashireva, L.  A., Popova, N. O., Alifanov, V. V., Goldberg, V. E. , Kovalenko, E. I., Artamonova, E. V., Manikhas, A. G. , Ponomarenko, D. M., Levchenko, N. V., Rossokha, E. I., Krasilnikova, S. Yu. , Zafirova, M. A., Perelmuter, V. M. 

“…Background . Triple negative breast cancer has no specific treatment sites for chemotherapy and is unfavorable in terms of prognosis. One of the drugs widely…”
Get full text

Tumor-Infiltrating Lymphocytes in Breast Cancer. Association with Clinical and Pathological Parameters by Zabotina, T. N., Korotkova, O. V., Chertkova, A. I., Zakharova, E. N., Tabakov, D. V., Dzhgamadze, N. T., Savostikova, M. V., Artamonova, E. V., Khailenko, V. A., Kovalenko, E. I., Kadagidze, Z. G.

“…In patients with primary resectable breast cancer, a positive correlation between the age and the count of CD16 + lymphocytes and a negative correlation of…”
Get full text

Clinical significance of changes in the expression level of markers of surrogate breast cancer subtypes in recurrent and metastatic foci (literature review) by Krumin, Yu. S., Khaylenko, V. A., Kozlov, N. A., Cheremis, G. Yu, Petrovskyy, A. V., Khaylenko, D. V., Artamonova, E. V., Kovalenko, E. I.

“…The article analyzes data from the world literature for the period from 2005 to 2020 on the relationship between the variability of immunohistochemical…”
Get full text

Analysis of the association of the polymorphism of the CLIC1, MSH5, C6orf26, C6orf25 genes with the expression level of the HSPA1B gene by Vavilovа, Yu. D., Boyko, A. A., Kovalenko, E. I., Grechikhina, M. V., Shustova, O. A., Azhikina, T. L., Sapozhnikov, A. M.

“…Heat  shock proteins (HSP, heat  shock proteins) form one of the cellular  molecular systems with chaperone activity, aimed  at stabilizing  the structure of…”
Get full text

A Novel Approach to Anticancer Therapy: Molecular Modules Based on the Barnase:Barstar Pair for Targeted Delivery of HSP70 to Tumor Cells by Sapozhnikov, A M, Klinkova, A V, Shustova, O A, Grechikhina, M V, Kilyachus, M S, Stremovskiy, O A, Kovalenko, E I, Deyev, S M

“…One important distinction between many tumor cell types and normal cells consists in the translocation of a number of intracellular proteins, in particular the…”
Get full text

TREATMENT OF BREAST CANCER WITH METASTATIC CONTRALATERAL AXILLARY LYMPH NODES: CASE REPORT AND LITERATURE REVIEW by Amosova, V. A., Petrovsky, A. V., Chernykh, M. V., Kovalenko, E. I., Frolova, M. A., Valiev, R. K., Nechushkin, M. I., Kirsanov, V. U., Vysotskaya, I. V., Avtomonov, D. E.

“…Background. until now, only a few reports have been available on clinical management of breast cancer patients with metastases to the contralateral axillary…”
Get full text

DISTRIBUTION OF MICA ALLELES IN THE RUSSIAN POPULATION by Kanevskiy, L. M., Grechikhina, M. V., Kuzmina, E. G., Mushkarina, T. Yu, Spelkov, A. A., Streltsova, M. A., Kovalenko, E. I.

“…Stress factors, infections, tumor transformation of the cells of organism induce the expression of MICA protein, which is a ligand for the NKG2D receptor of NK…”
Get full text

Tactics for minimizing risk of increasing estradiol against the background of aromatase inhibitors in combination with gonadotropin releasing hormone agonists in adjuvant therapy for breast cancer in premenopausal patients. Pilot study results by I. B. Kononenko, A. V. Snegovoi, L. V. Manzyuk, E. I. Kovalenko, V. Yu. Selchuk

“…Aromatase inhibitor (AI) combined with Gonadotropin-releasing hormone agonist (GnRH-a) have been recognized as an effective approach to adjuvant…”
Get full text